Novartis pays $729 mn to settle US charges that it paid doctors kickbacks

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs

Novartis India MD Milan Paleja to step down with effect from May 31
A Novartis spokesman said the costs of the settlement were covered by provisions that it had already made
Jonathan Stempel | Reuters New York
2 min read Last Updated : Jul 02 2020 | 1:17 PM IST

Novartis AG agreed to pay more than $729 million to settle U.S. government charges it paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said on Wednesday.

The Swiss drugmaker will pay $678 million to resolve claims it organised tens of thousands of sham educational events where it lavished doctors with exorbitant speaker fees, expensive dinners and alcohol to induce them to prescribe its cardiovascular and diabetes drugs more often.

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs.

Both settlements resolved civil charges that Novartis violated the federal False Claims Act.

A Novartis spokesman said the costs of the settlement were covered by provisions that it had already made.

Its shares were indicated 0.4% higher in pre-market activity on Thursday.

Acting U.S. Attorney Audrey Strauss in Manhattan called the incentives for doctors "nothing more than bribes" and said federal healthcare programs paid hundreds of millions of dollars in reimbursements for prescriptions tainted by kickbacks.

"Giving these cash payments and other lavish goodies interferes with the duty of doctors to choose the best treatment for their patients and increases drug costs for everyone," Strauss said in a statement.

The Justice Department said the speaker programs and other promotional events occurred from 2002 to 2011, while the co-payments were made from 2010 to 2014.

In connection with the settlements, Novartis agreed to curtail its speaker programs and enter a five-year corporate integrity agreement.

It also accepted responsibility for many allegations underlying the larger settlement, for which it set aside funds in July 2019.

"We are a different company today, with new leadership, a stronger culture and a more comprehensive commitment to ethics," CEO Vas Narasimhan said in a statement.

The $678 million payout includes $591.4 million in damages to the U.S. government, a $38.4 million forfeiture for violating an anti-kickback statute and $48.2 million to U.S. states.

 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :NovartisUS government

Next Story